• Rein Therapeutics posted a net loss of $5.84 million for three months ended March 31, 2026, widening from $5.5 million a year earlier.
• Operating loss narrowed to $5.23 million as total operating expenses fell to $5.23 million from $5.61 million.
• Other expense swung to $608,000 from other income of $108,000, driven primarily by amortization of discount on notes payable tied to promissory notes.
• Cash and cash equivalents totaled $4.4 million at March 31, 2026; net proceeds of about $53.1 million from a May 2026 stock offering are expected to fund operations into first quarter 2028.
• First patient was dosed in March in Phase 2 RENEW trial of lead candidate LTI-03 in idiopathic pulmonary fibrosis; initial interim topline data expected in fourth quarter 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-225352), on May 15, 2026, and is solely responsible for the information contained therein.